120 related articles for article (PubMed ID: 29680736)
1. Computational approach for generating robust models for discovering novel molecules as Cyclin Dependent Kinase 4 inhibitors.
Divya V; Pushpa VL; Sarithamol S; Manoj KB
J Mol Graph Model; 2018 Jun; 82():48-58. PubMed ID: 29680736
[TBL] [Abstract][Full Text] [Related]
2. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
[TBL] [Abstract][Full Text] [Related]
3. Molecular docking and MD simulation studies of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as novel inhibitors targeted to CDK2/4/6.
Liang JD; Zhang YE; Qin F; Chen WN; Jiang WM; Fang Z; Liang XL; Zhang Q; Li J
J Cancer Res Clin Oncol; 2024 Jun; 150(6):302. PubMed ID: 38856753
[TBL] [Abstract][Full Text] [Related]
4. An in silico approach to discover the best molecular modeling strategy for designing novel CDK4 inhibitors.
Vasanthakumari D; Vadakkethil Lalithabhai P; Kanthimathi Bahuleyan M
Chem Biol Drug Des; 2019 Apr; 93(4):556-569. PubMed ID: 30536727
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore generation, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on benzamide analogues as FtsZ inhibitors.
Tripathy S; Azam MA; Jupudi S; Sahu SK
J Biomol Struct Dyn; 2018 Sep; 36(12):3218-3230. PubMed ID: 28938860
[TBL] [Abstract][Full Text] [Related]
6. Insight into the interactions between novel isoquinolin-1,3-dione derivatives and cyclin-dependent kinase 4 combining QSAR and molecular docking.
Zheng J; Kong H; Wilson JM; Guo J; Chang Y; Yang M; Xiao G; Sun P
PLoS One; 2014; 9(4):e93704. PubMed ID: 24722522
[TBL] [Abstract][Full Text] [Related]
7. 2D-QSAR study, molecular docking, and molecular dynamics simulation studies of interaction mechanism between inhibitors and transforming growth factor-beta receptor I (ALK5).
Jiang MN; Zhou XP; Sun DR; Gao H; Zheng QC; Zhang HX; Liang D
J Biomol Struct Dyn; 2018 Nov; 36(14):3705-3717. PubMed ID: 29064324
[TBL] [Abstract][Full Text] [Related]
8. A combination of pharmacophore modeling, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on PDE4 enzyme inhibitors.
Tripuraneni NS; Azam MA
J Biomol Struct Dyn; 2016 Nov; 34(11):2481-92. PubMed ID: 26587754
[TBL] [Abstract][Full Text] [Related]
9. Selective ATP competitive leads of CDK4: Discovery by 3D-QSAR pharmacophore mapping and molecular docking approach.
Rondla R; PadmaRao LS; Ramatenki V; Haredi-Abdel-Monsef A; Potlapally SR; Vuruputuri U
Comput Biol Chem; 2017 Dec; 71():224-229. PubMed ID: 29153893
[TBL] [Abstract][Full Text] [Related]
10. Effect of hydrophobic and hydrogen bonding interactions on the potency of ß-alanine analogs of G-protein coupled glucagon receptor inhibitors.
Venugopal PP; Das BK; Soorya E; Chakraborty D
Proteins; 2020 Feb; 88(2):327-344. PubMed ID: 31443129
[TBL] [Abstract][Full Text] [Related]
11. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
[TBL] [Abstract][Full Text] [Related]
12. A mechanistic approach to explore novel HDAC1 inhibitor using pharmacophore modeling, 3D- QSAR analysis, molecular docking, density functional and molecular dynamics simulation study.
Choubey SK; Jeyaraman J
J Mol Graph Model; 2016 Nov; 70():54-69. PubMed ID: 27668885
[TBL] [Abstract][Full Text] [Related]
13. Analysing the Effect of Mutation on Protein Function and Discovering Potential Inhibitors of CDK4: Molecular Modelling and Dynamics Studies.
N N; Zhu H; Liu J; V K; C GP; Chakraborty C; Chen L
PLoS One; 2015; 10(8):e0133969. PubMed ID: 26252490
[TBL] [Abstract][Full Text] [Related]
14. Structural requirements of pyrido[2,3-d]pyrimidin-7-one as CDK4/D inhibitors: 2D autocorrelation, CoMFA and CoMSIA analyses.
Caballero J; Fernández M; González-Nilo FD
Bioorg Med Chem; 2008 Jun; 16(11):6103-15. PubMed ID: 18468903
[TBL] [Abstract][Full Text] [Related]
15. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
Halder AK; Saha A; Saha KD; Jha T
J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
[TBL] [Abstract][Full Text] [Related]
16. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
Zhang G; Ren Y
Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939
[TBL] [Abstract][Full Text] [Related]
17. Structure-based and multiple potential three-dimensional quantitative structure-activity relationship (SB-MP-3D-QSAR) for inhibitor design.
Du QS; Gao J; Wei YT; Du LQ; Wang SQ; Huang RB
J Chem Inf Model; 2012 Apr; 52(4):996-1004. PubMed ID: 22480344
[TBL] [Abstract][Full Text] [Related]
18. Molecular modeling studies on series of Btk inhibitors using docking, structure-based 3D-QSAR and molecular dynamics simulation: a combined approach.
Balasubramanian PK; Balupuri A; Cho SJ
Arch Pharm Res; 2016 Mar; 39(3):328-39. PubMed ID: 26699616
[TBL] [Abstract][Full Text] [Related]
19. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
20. Insight into the structural requirements of thiophene-3-carbonitriles-based MurF inhibitors by 3D-QSAR, molecular docking and molecular dynamics study.
Azam MA; Jupudi S
J Recept Signal Transduct Res; 2017 Oct; 37(5):522-534. PubMed ID: 28768454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
